WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206067
Description: Iproplatin is a synthetic second-generation platinum-containing compound related to cisplatin. Iproplatin binds to and forms DNA crosslinks and platinum-DNA adducts, resulting in DNA replication failure and cell death. Although less prone to glutathione inactivation compared to cisplatin, resistance to this agent has been observed in vitro due to repair of platination damage by tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
MedKoo Cat#: 206067
Chemical Formula: C6H20Cl2N2O2Pt
Exact Mass: 417.05496
Molecular Weight: 418.22
Elemental Analysis: C, 17.23; H, 4.82; Cl, 16.95; N, 6.70; O, 7.65; Pt, 46.65
Synonym: CHIP; Code name: JM9; JM-9; JM 9.
IUPAC/Chemical Name: cis,trans,cis-Dichlorodihydroxobis(isopropylamine)platinum
InChi Key: FXSKHQLAUMGYJK-UHFFFAOYSA-J
InChi Code: InChI=1S/2C3H9N.2ClH.2H2O.Pt/c2*1-3(2)4;;;;;/h2*3H,4H2,1-2H3;2*1H;2*1H2;/q;;;;;;+4/p-4
SMILES Code: CC([NH2+][Pt-2]([NH2+]C(C)C)(O)(Cl)(Cl)O)C.
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 418.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Volckova E, Weaver E, Bose RN. Insight into the reactive form of the anticancer agent iproplatin. Eur J Med Chem. 2008 May;43(5):1081-4. Epub 2007 Jul 10. PubMed PMID: 17707553.
2: Pawinski A, Crowther D, Keizer HJ, VoÃ»te PA, Somers R, van Glabbeke M, Lentz MA, van Oosterom AT. The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma. Eur J Cancer. 1999 Jan;35(1):163-4. PubMed PMID: 10211107.
3: Zhong W, Zhang Q, Yan Y, Yue S, Zhang B, Tang W. Interaction of sodium chloroplatinate and iproplatin with metallothionein in vivo. J Inorg Biochem. 1997 May 15;66(3):159-64. PubMed PMID: 9130391.
4: Pendyala L, Perez R, Weinstein A, Zdanowicz J, Creaven PJ. Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line. Cancer Chemother Pharmacol. 1997;40(1):38-44. PubMed PMID: 9137527.
5: He Q, Bhujwalla ZM, Maxwell RJ, Griffiths JR, Glickson JD. Proton NMR observation of the antineoplastic agent Iproplatin in vivo by selective multiple quantum coherence transfer (Sel-MQC). Magn Reson Med. 1995 Mar;33(3):414-6. PubMed PMID: 7760709.
6: Castleberry RP, Cantor AB, Green AA, Joshi V, Berkow RL, Buchanan GR, Leventhal B, Mahoney DH, Smith EI, Hayes FA. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1994 Aug;12(8):1616-20. PubMed PMID: 8040674.
7: Vermorken JB, Gundersen S, Clavel M, Smyth JF, Dodion P, Renard J, Kaye SB. Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center. Ann Oncol. 1993 Apr;4(4):303-6. PubMed PMID: 8518220.
8: Cappelaere P, Guiochet N, Bastit P, Favre R, Vanderburg M, Goupil A, Chauvergne J, Thomas D, Van Glabbeke M, Armand JP. Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lung. Eur J Cancer. 1993;29A(8):1216. PubMed PMID: 8518037.
9: Hubbard KP, Pazdur R, Ajani JA, Braud E, Blaustein A, King M, Llenado-Lee M, Winn R, Levin B, Abbruzzese JL. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol. 1992 Dec;15(6):524-7. PubMed PMID: 1449117.
10: Murphy BA, Motzer RJ, Bosl GJ. Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. Invest New Drugs. 1992 Nov;10(4):327-30. PubMed PMID: 1336770.